Sorry, you need to enable JavaScript to visit this website.

White paper | Small Molecule APIs: aligning drug strategy with partnering strategy

September 2019, Small Molecule APIs

Development of novel small molecule active pharmaceutical ingredients (APIs) is increasingly turned over to outsourced partners who have become the primary drivers of the product’s overall development and go-to-market strategy. With hundreds of potential partners that drug owners can choose from to develop and manufacture small molecule APIs, choosing the best partner can be a challenging task.

In this white paper, we explore the importance of purposefully aligning the overall drug development strategy with a partnering strategy. We also review how increasing development of novel drugs are also impacting the industry’s go-to-market efforts, driving new demand for expert small molecule API suppliers. Finally, we consider how small molecule API development projects can be executed by leveraging the experience of embedded contract development and manufacturing (CDMO) partners.

You can download the full white paper by completing the form below.

 
1 Start 2 Complete

Service of interest (select only one)*

Send me news and updates
We would like to send you information which Pfizer CentreOne believes may be of value to you and relevant to your work. If you would like to receive such information, please tick the box below.

By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Pfizer’s processing of your personal data, including its transfer internationally and to third parties, in accordance with the
Pfizer Privacy Policy and Pfizer website terms of use.